 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Research Articles |
OBJECTIVE: To report a case of nonoliguric acute renal failure secondary to use of celecoxib in a patient with rheumatoid arthritis. CASE SUMMARY: A 43-year-old Hispanic woman started receiving celecoxib 200 mg/d for treatment of rheumatoid arthritis. Fourteen days after initiating therapy, she developed nonoliguric acute renal failure. Celecoxib was discontinued. Renal function improved, but had not returned to normal 30 days after presentation. DISCUSSION: Only 2 cases of reversible oliguric acute renal failure and volume overload have been reported 13 and 14 days after initiating therapy with celecoxib. Renal function in the 2 patients returned to baseline after treatment with diuretics. To our knowledge, the development of nonoliguric acute renal failure secondary to treatment with celecoxib has not previously been reported. CONCLUSIONS: Celecoxib can probably result in reversible, or nonoliguric, acute renal failure. Although renal function improves after discontinuation of celecoxib, it may not return to baseline. Celecoxib should be used cautiously in individuals at risk of developing acute renal failure.
This article has been cited by other articles:
|
|
 |
|
  M. M Verrico, R. J Weber, T. P McKaveney, N. T Ansani, and A. L Towers Adverse Drug Events Involving COX-2 Inhibitors Ann. Pharmacother., September 1, 2003; 37(9): 1203 - 1213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Robin Goodfellow Rheumatology, May 1, 2002; 41(5): 598 - 598. [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
